Advocacy News

• California Committee Advances Copay Accumulator Bill.  The California Senate Committee on Health unanimously advanced SB 1199, legislation that. would ban copay accumulator programs, on April 22. ASCO supported the bill along with the  Association of Northern California Oncologists and the Medical Oncology Association of Southern California. 

  Read More

Corporate Member News

• Bristol Myers Squibb invites ANCO members to join them at ASCO for their 7th annual gathering to discuss ongoing efforts to Conquer Veteran Cancer, Together.  The event will take place on Sunday, May 31, 2026, from 9:30–11:30 AM CT at the Hyatt Regency McCormick Place (Regency Ballroom AB).

• Tarlatamab-dlle (IMDELLTRA®) is an NCCN® Category 1, Preferred subsequent treatment for adult patients (PS 0-2) with ES-SCLC who have progressed on or after platinum-based chemotherapy.  To access the full recommendations, please visit the NCCN® website: SCLC Guidelines.

Read More

• FDA approves :umakras® (sotorasib), Amgen in combination with vectibix® (panitumumab) for chemorefractory kras G12C-mutated metastatic colorectal cancer.

Read More

• FDA grants full approval to Amgen's IMDELLTRA® in extensive stage small cell lung cancer. 

Read More

Coding and Reimbursement Updates

• This Month’s E-Reiumbursement Newsletter from Bobbi Buell for April 23, 2026

Read More